RAS/KRAS

News

RevMed nears EU okay for pancreatic cancer drug Rasonque

Revolution Medicines is just weeks away from getting EU approval for its keenly anticipated oral RAS drug Rasonque for pancreatic cancer.

News

MSD takes a $400m bite of SciBrunch's KRAS drug

MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

News

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

News

Firefly in a jar illustration on black background

J&J lights up $1bn offer for pan-KRAS developer Firefly

Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.

RevMed nears EU okay for pancreatic cancer drug Rasonque

MSD takes a $400m bite of SciBrunch's KRAS drug

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Roche's KRAS drug tops its rivals in lung cancer trial

J&J lights up $1bn offer for pan-KRAS developer Firefly

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

RAS/KRAS

Editor's Picks